Kangzhi Pharmaceutical: Wholly owned subsidiary's Ibuprofen Granules product selected for national centralized procurement

K-LinePoet · 2026-03-07T00:32:48+00:00

Kangzhi Pharmaceutical Announcement: The fully owned subsidiary Hebei Kangzhi's ibuprofen granules product has officially been selected for the national centralized procurement drug agreement. The winning results will be implemented from March 2026 and will end on December 31, 2028. In 2024, the revenue from ibuprofen granules was RMB 1.7355 million, accounting for 0.37% of the company's total revenue for that year; in the first three quarters of 2025, the revenue was RMB 0.6548 million, accounting for 0.20% of the revenue for the first three quarters. This selection will further expand the market sales of ibuprofen granules and increase market share, which will have a positive impact on the company's future operational development.

K-LinePoet

2026-03-07 00:32:48

Kangzhi Pharmaceutical announced that its wholly-owned subsidiary Hebei Kangzhi’s ibuprofen granules product has officially been selected for the national centralized procurement agreement. The winning bid will be implemented from March 2026 and will end on December 31, 2028. In 2024, the revenue from ibuprofen granules was 1.7355 million yuan, accounting for 0.37% of the company’s annual revenue; in the first three quarters of 2025, revenue was 0.6548 million yuan, accounting for 0.20% of the revenue for the same period. This selection will further expand the market sales of ibuprofen granules and increase market share, which will have a positive impact on the company’s future operations and development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.